

Josã© Tadeu Stefano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2499124/publications.pdf>

Version: 2024-02-01

54
papers

1,438
citations

361296

20
h-index

330025

37
g-index

56
all docs

56
docs citations

56
times ranked

2838
citing authors

#	ARTICLE	IF	CITATIONS
1	173 CONVENTIONAL AND NOVEL CARDIOVASCULAR RISK FACTORS IN LIVER TRANSPLANT RECIPIENTS (LTR). <i>Journal of Hepatology</i> , 2012, 56, S75-S76.	1.8	216
2	Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 369-384.	1.1	96
3	Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. <i>Hepatology Research</i> , 2008, 38, 159-165.	1.8	93
4	A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 49, 1055-1061.	1.8	91
5	Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. <i>Clinical Nutrition</i> , 2016, 35, 578-586.	2.3	85
6	Effects of Hepatitis C virus on cardiovascular risk in infected patients: A comparative study. <i>International Journal of Cardiology</i> , 2013, 164, 221-226.	0.8	73
7	Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 357-361.	1.4	69
8	Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH – Proteomic and lipidomic insight. <i>Clinical Nutrition</i> , 2018, 37, 1474-1484.	2.3	66
9	Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). <i>Annals of Hepatology</i> , 2019, 18, 416-421.	0.6	49
10	Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease. <i>Menopause</i> , 2016, 23, 876-883.	0.8	44
11	Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. <i>Annals of Hepatology</i> , 2019, 18, 466-471.	0.6	42
12	Advanced glycated albumin isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene expression impairing ABCA1-mediated reverse cholesterol transport. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, 29, 66-76.	1.7	35
13	Gluco-lipidic indices in treated hypothyroidism associated with nonalcoholic fatty liver disease. <i>Arquivos De Gastroenterologia</i> , 2011, 48, 186-189.	0.3	34
14	Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis. <i>Obesity Surgery</i> , 2010, 20, 906-912.	1.1	28
15	Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 245-251.	1.4	27
16	Hypocaloric high-protein diet improves clinical and biochemical markers in patients with nonalcoholic fatty liver disease (NAFLD). <i>Nutricion Hospitalaria</i> , 2014, 29, 94-101.	0.2	27
17	Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2006, 12, 3821.	1.4	27
18	Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. <i>Annals of Hepatology</i> , 2020, 19, 622-626.	0.6	23

#	ARTICLE	IF	CITATIONS
19	Hepatic gene expression profile associated with non-alcoholic steatohepatitis protection by S-nitroso-N-acetylcysteine in ob/ob mice. <i>Journal of Hepatology</i> , 2006, 45, 725-733.	1.8	22
20	Genetic polymorphisms and oxidative stress in non-alcoholic steatohepatitis (NASH): A mini review. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, S35-S40.	0.7	22
21	Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2021, 20, 100253.	0.6	21
22	Nonalcoholic Steatohepatitis (NASH) in OB/OB Mice Treated with Yo Jyo Hen Shi Ko (YHK): Effects on Peroxisome Proliferator-Activated Receptors (PPARs) and Microsomal Triglyceride Transfer Protein (MTP). <i>Digestive Diseases and Sciences</i> , 2007, 52, 3448-3454.	1.1	19
23	Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 428-432.	0.6	19
24	N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 184-190.	0.3	18
25	Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?. <i>Liver International</i> , 2011, 31, 377-385.	1.9	16
26	Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 361-364.	1.4	16
27	S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. <i>Drug Design, Development and Therapy</i> , 2013, 7, 553.	2.0	16
28	IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). <i>Arquivos De Gastroenterologia</i> , 2019, 56, 431-439.	0.3	15
29	Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob mice. <i>Biochemical Pharmacology</i> , 2007, 74, 290-297.	2.0	14
30	Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 330-335.	0.6	13
31	Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 8667.	1.4	13
32	Aerobic Exercise Training Exerts Beneficial Effects Upon Oxidative Metabolism and Non-Enzymatic Antioxidant Defense in the Liver of Leptin Deficiency Mice. <i>Frontiers in Endocrinology</i> , 2020, 11, 588502.	1.5	11
33	S-Nitroso-N-acetylcysteine induces de-differentiation of activated hepatic stellate cells and promotes antifibrotic effects in vitro. <i>Nitric Oxide - Biology and Chemistry</i> , 2011, 25, 360-365.	1.2	10
34	Fatty Pancreas: Disease or Finding?. <i>Clinics</i> , 2021, 76, e2439.	0.6	10
35	Ischemic Preconditioning-Like Effect of Polyunsaturated Fatty Acid-Rich Diet on Hepatic Ischemia/Reperfusion Injury. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1679-1688.	0.9	9
36	Genetic ancestry analysis in non-alcoholic fatty liver disease patients from Brazil and Portugal. <i>World Journal of Hepatology</i> , 2015, 7, 1433.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Association of a variant in the regulatory region of NADPH oxidase 4 gene and metabolic syndrome in patients with chronic hepatitis C. <i>European Journal of Medical Research</i> , 2015, 20, 45.	0.9	6
38	Evolution of Biomarkers of Atherogenic Risk in Liver Transplantation Recipients. <i>Transplantation Proceedings</i> , 2018, 50, 3650-3655.	0.3	6
39	African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population. <i>Annals of Hepatology</i> , 2022, 27, 100728.	0.6	5
40	Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD): a multicenter prospective study. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 350-352.	0.7	4
41	Methylene tetrahydrofolate reductase (MTHFR) and vascular endothelial growth factor (VEGF) polymorphisms in Brazilian patients with Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). <i>Clinics</i> , 2021, 76, e2881.	0.6	4
42	Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients. <i>Biomedicines</i> , 2021, 9, 1751.	1.4	4
43	<p>Effects of Aerobic Exercise Protocol on Genes Related to Insulin Resistance and Inflammation in the Pancreas of ob/ob Mice with NAFLD</p>. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 223-234.	1.0	3
44	18F-FDG PET/CT AS AN ASSESSMENT TOOL OF HEPATOCELLULAR CARCINOMA SECONDARY TO NON-ALCOHOLIC FATTY LIVER DISEASE DEVELOPMENT IN EXPERIMENTAL MODEL. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 45-50.	0.3	2
45	Hypolactasia is associated with insulin resistance in nonalcoholic steatohepatitis. <i>World Journal of Hepatology</i> , 2016, 8, 1019.	0.8	2
46	Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. <i>Metabolic Syndrome and Related Disorders</i> , 2022, , .	0.5	2
47	del 11(q23) as a prognostic factor of iron overload in refractory anemia with ringed sideroblasts. <i>Sao Paulo Medical Journal</i> , 1997, 115, 1513-1515.	0.4	1
48	The gut microbiome of lean patients with non-alcoholic steatohepatitis: comparison with overweight/obese counterparts and healthy subjects, correlation with dietary intake and liver histology. <i>Journal of Hepatology</i> , 2017, 66, S166-S167.	1.8	1
49	O-14 A SYNERGISTIC EFFECT OF PNPLA3 GENE POLYMORPHISM AND INSULIN RESISTANCE INCREASES THE RISK TO NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME. <i>Annals of Hepatology</i> , 2021, 24, 100501.	0.6	1
50	[18F]FDG PET imaging evaluation on non-alcoholic fatty liver disease and hepatocellular carcinoma model treated with sorafenib. <i>Hepatoma Research</i> , 2018, 4, 35.	0.6	1
51	S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Corrigendum]. <i>Drug Design, Development and Therapy</i> , 0, , 971.	2.0	0
52	Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD score) on NAFLD in a mixed Latin American population. <i>Journal of Hepatology</i> , 2020, 73, S406-S407.	1.8	0
53	Yo Jyo Hen Shi Ko (YHK) Modulates the Expression of Proteins Involved in de novo Lipogenesis and Lipid Exportation in Experimental Nonalcoholic Steatohepatitis (NASH). <i>Journal of Pharmacy and Nutrition Sciences (discontinued)</i> , 2013, 3, 48-58.	0.2	0
54	HCC in Patients with NAFLD/NASH. , 2020, , 191-203.		0